Picture of Xvivo Perfusion AB logo

XVIVO — Xvivo Perfusion AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMid CapFalling Star

Sweden's XVIVO Q1 net sales growth tops expectations, swings to profit

Overview

Sweden medical technology firm's Q1 net sales rose 10%, beating analyst expectations

Q1 EPS increased to SEK 1.15 from a loss last year

Company announced CFO transition during the quarter

Outlook

Company did not provide specific guidance for the current quarter or full year

Result Drivers

THORACIC SALES GROWTH - Thoracic sales increased by 27% in local currencies, supporting overall revenue growth

ABDOMINAL SALES GROWTH - Abdominal sales rose by 24% in local currencies, contributing to higher net sales

SERVICE SALES DECLINE - Services sales decreased by 10%, partially offsetting growth in other segments

Company press release: ID:nMFN6jk7TC

Key Details

MetricBeat/MissActualConsensus Estimate
Q1 SalesBeatSEK 241 mlnSEK 238.25 mln (4 Analysts)
Q1 EPSSEK 1.15
Q1 Net IncomeSEK 36.30 mln
Q1 EBITSEK 31.90 mln
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell" The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy" Wall Street's median 12-month price target for Xvivo Perfusion AB is SEK337.00, about 12.3% above its April 23 closing price of SEK300.00 The stock recently traded at 63 times the next 12-month earnings vs. a P/E of 43 three months ago For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Xvivo Perfusion AB

See all news